Abstract
Fourteen days' culture of human peripheral blood lymphocytes (PBL) with recombinant interleukin 2 (rIL 2) or T cell growth factor (TCGF) results in the generation of lymphokine-activated killer (LAK) effector cells which have the unique property of lysing natural killer (NK)-resistant human tumor cells, Daudi, as well as NK-sensitive, K562 cells. LAK cells were generated from both normal and gastric cancer patients' PBL. However, LAK cell activities induced by rIL 2 or TCGF decreased with the progress of the tumor growth. In addition, TCGF-induced LAK cell activities were found to be lower than the rIL 2-induced LAK cell activities. Different mechanisms may be involved in the decreases of the rIL 2-induced and TCGF-induced LAK cell activities. This study further demonstrates that the cell types involved are also heterogeneous, as determined by phenotypic characteristics. The LAK-effector cell type was analyzed by two-color flow cytometry. RIL 2-induced LAK cells showed increased proportions of CD4+Leu 8- and Leu 7+CD16-, and a decreased proportion of CD8+CD11- cells, which are believed to be associated with killer T cell functions. In contrast, TCGF-induced LAK cells revealed significantly increased proportions of CD8+CD11- and...Continue Reading
References
Jul 14, 1977·Nature·S Gillis, K A Smith
Aug 23, 1979·Nature·J M Zarling, F H Bach
Jan 1, 1989·Cancer Immunology, Immunotherapy : CII·T EbiharaT Osuga
Nov 15, 1985·Cancer·S KoyamaS Fujimoto
Jan 1, 1986·Cancer Immunology, Immunotherapy : CII·K ShiibaK Kumagai
Feb 1, 1985·European Journal of Cancer & Clinical Oncology·S KoyamaS Fujimoto
Jan 1, 1988·Cancer Immunology, Immunotherapy : CII·E A GrimmL B Owen-Schaub
Jun 1, 1987·The Journal of Surgical Research·J M SkibberS A Rosenberg
Apr 1, 1988·Clinical Cardiology·K TakashibaH Ebihara
Jun 1, 1982·The Journal of Experimental Medicine·E A GrimmS A Rosenberg
May 1, 1984·The Journal of Experimental Medicine·S RichC Arhelger
Sep 1, 1984·Journal of Clinical Immunology·L T ClementA Landay
Mar 30, 1984·Science·S A RosenbergD F Mark
Oct 1, 1983·The Journal of Experimental Medicine·E A GrimmS A Rosenberg
Mar 1, 1983·The Journal of Experimental Medicine·E A GrimmS A Rosenberg
Jan 1, 1983·The Journal of Experimental Medicine·T AboC M Balch
Jul 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·S C MeuerE L Reinherz
Jan 1, 1987·Immunology Today·R B HerbermanA Uchida
Jan 1, 1987·Immunology Today·P Hersey, R Bolhuis
Citations
Jan 1, 1997·Journal of Cancer Research and Clinical Oncology·S Koyama
Jan 1, 1992·Journal of Cancer Research and Clinical Oncology·S KoyamaK Fukao
Feb 1, 1994·Japanese Journal of Cancer Research : Gann·S Koyama
Sep 1, 1990·Cancer·T EbiharaS Koyama
Jan 1, 1994·Journal of Cancer Research and Clinical Oncology·S Koyama, K Fukao